Experimental investigation of a combinational iron chelating protoporphyrin IX prodrug for fluorescence detection and photodynamic therapy
Authors:
Open Access
- 4 July 2021
- journal article
- research article
- Published by Springer Nature in Lasers in Medical Science
- Vol. 37 (2) , 1155-1166
Abstract
Photodynamic therapy (PDT) is an oxygen-dependent, light-activated, and locally destructive drug treatment of cancer. Protoporphyrin IX (PpIX)-induced PDT exploits cancer cells’ own innate heme biosynthesis to hyper-accumulate the naturally fluorescent and photoactive precursor to heme, PpIX. This occurs as a result of administering heme precursors (e.g., aminolevulinic acid; ALA) because the final step of the pathway (the insertion of ferrous iron into PpIX by ferrochelatase to form heme) is relatively slow. Separate administration of an iron chelating agent has previously been demonstrated to significantly improve dermatological PpIX-PDT by further limiting heme production. A newly synthesized combinational iron chelating PpIX prodrug (AP2-18) has been assessed experimentally in cultured primary human cells of bladder and dermatological origin, as an alternative photosensitizing agent to ALA or its methyl or hexyl esters (MAL and HAL respectively) for photodetection/PDT. Findings indicated that the technique of iron chelation (either through the separate administration of the established hydroxypyridinone iron chelator CP94 or the just as effective combined AP2-18) did not enhance either PpIX fluorescence or PDT-induced (neutral red assessed) cell death in human primary normal and malignant bladder cells. However, 500 µM AP2-18 significantly increased PpIX accumulation and produced a trend of increased cell death within epithelial squamous carcinoma cells. PpIX accumulation destabilized the actin cytoskeleton in bladder cancer cells prior to PDT and resulted in caspase-3 cleavage/early apoptosis afterwards. AP2-18 iron chelation should continue to be investigated for the enhancement of dermatological PpIX-PDT applications but not bladder photodetection/PDT.Keywords
Funding Information
- Medical Research Council UK
- Killing Cancer UK
This publication has 42 references indexed in Scilit:
- Iron speciation in the cytosol: an overviewDalton Transactions, 2012
- Comprehensive analysis of the genome transcriptome and proteome landscapes of three tumor cell linesGenome Medicine, 2012
- Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinomaBritish Journal of Dermatology, 2008
- Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinomaJournal of Cancer Research and Clinical Oncology, 2008
- Direct Comparison of δ-Aminolevulinic Acid and Methyl-Aminolevulinate-Derived Protoporphyrin IX Accumulations Potentiated by Desferrioxamine or the Novel Hydroxypyridinone Iron Chelator CP94 in Cultured Human CellsPhotochemistry and Photobiology, 2007
- The advantages of aminolevulinic acid photodynamic therapy in dermatologyJournal of Dermatological Treatment, 2002
- The immortalized UROtsa cell line as a potential cell culture model of human urothelium.Environmental Health Perspectives, 2001
- Cell-type Specific Protoporphyrin IX Metabolism in Human Bladder Cancer in vitro¶Photochemistry and Photobiology, 2000
- Transurethral Resection and Surveillance of Bladder Cancer Supported by 5-Aminolevulinic Acid-Induced Fluorescence EndoscopyEuropean Urology, 1999
- Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of miceJournal of Photochemistry and Photobiology B: Biology, 1995